Clinical Trial

Effects of Semaglutide in HIV-Associated Lipohypertrophy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.
Protocol Amendment History 1 change
minor Completion pushed: 2026-02-28 -> 2026-09-01 2026-05-05
Trial Details
NCT Number NCT04019197
Lead Sponsor Case Western Reserve University
Collaborators: Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions HIV/AIDS, Lipohypertrophy, Obesity
Enrollment 108 participants
Start Date 2019-05-16
Primary Completion 2024-04-30 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-04